AstraZeneca's Imfinzi regimen demonstrated statistically significant and clinically meaningful improvement in DFS for ...
Positive high-level results from the POTOMAC phase III trial showed one year of treatment with AstraZeneca’s Imfinzi (durvalumab) plus standard-of-care BCG induction and maintenance therapy demonstrated a statistically significant and clinically meaningful …